On July 29, 2016, post-market, ADMA announced that it had received a complete response letter from the U.S. Food and Drug Administration ("FDA") regarding the Company's RI-002 product which identified several unresolved issues from inspection and deficiencies at ADMA's third-party contract manufacturers and its contract drug substance and product manufacturer. Following this news, ADMA stock dropped as much as $2.85 per share, or 36.3%, to $5.00 during intraday trading on August 1, 2016, the next trading day.
If you are aware of any facts relating to this investigation, or purchased shares of ADMA, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/adma or by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-adma-biologics-inc-adma-300307081.html
SOURCE Bronstein, Gewirtz & Grossman, LLC